On Oct 25, 2023, Huadong Medicine's subsidiary, Hangzhou Zhongmeihuadong Pharmaceutical, was granted a "Notice of Acceptance" by the NMPA for their marketing application for Mirvetuximab Soravtansine Injection (IMGN853, HDM2002), co-developed with ImmunoGen.
This article summarized the latest R&D progress of trihexyphenidyl hydrochloride, the Mechanism of Action for trihexyphenidyl hydrochloride, and the drug target R&D trends for trihexyphenidyl hydrochloride.
This article summarized the latest R&D progress of trimetazidine hydrochloride, the Mechanism of Action for trimetazidine hydrochloride, and the drug target R&D trends for trimetazidine hydrochloride.
On Oct 25, 2023, Celltrion reported US FDA approval of Zymfentra (infliximab) for continued treatment of adult ulcerative colitis (UC) and Crohn's disease (CD) after intravenous infliximab treatment.
Attenuator in biotechnology refers to a nucleotide sequence in DNA that can lead to premature termination of transcription, a process found in bacteria and archaea.
This article summarized the latest R&D progress of viltolarsen, the Mechanism of Action for viltolarsen, and the drug target R&D trends for viltolarsen.
Yasheng Pharmaceutical presented updated clinical data for APG-1252 and Osimertinib to treat EGFR mutation lung cancer patients at the 2023 ESMO meeting on October 23, 2023.
Merck Company published an article in the Journal of Medicinal Chemistry (JMC) on the 20th of this month, reporting on the discovery process of LRRK2 inhibitor MK1468.